BPC-157 is a 15-residue gastric-juice-derived peptide; TB-500 is a synthetic fragment of thymosin beta-4. They are often studied in the same wound-healing models but operate via different cellular mechanisms.
Side-by-side comparison
| Property | BPC-157 | TB-500 |
|---|---|---|
| Origin | Gastric protective protein fragment | Thymosin beta-4 fragment |
| Sequence length | 15 aa | 17 aa |
| Primary mechanism | Angiogenesis, NO pathway | Actin sequestration, cell migration |
| Research models | Tendon, gut, vascular | Tissue repair, hair follicle, vascular |
| Half-life (research) | Short | Several hours |
| Often blended with | TB-500 | BPC-157 |
When researchers choose BPC-157
BPC-157 is typically selected when the research question targets its specific mechanism or when comparative data against TB-500 is the goal. ISO 17025 batch certificates are included with every shipment.
When researchers choose TB-500
TB-500 is typically selected when the research question targets its specific mechanism. Both compounds undergo the same HPLC and mass-spec verification.
Reconstitution and dosing
Both peptides reconstitute identically with bacteriostatic water. See the reconstitution guide for sterile technique and the dosage guide for concentration maths.
FAQ: BPC-157 vs TB-500
Can BPC-157 and TB-500 be combined in research?
Yes — a common research design pairs both as their mechanisms appear complementary. ThePeptideCode offers a BPC-157 + TB-500 blend.
Which shows results faster in animal tendon models?
BPC-157 tends to show earlier histology changes; TB-500 shows changes over a longer window. Always design according to your protocol.
Do they need different storage?
No — storage protocols are similar. Both store at 2–8 °C after reconstitution and can be aliquoted and frozen.